Together, these data suggest that either the pharmacological inhibitor A196 or the genetic inhibition of KMT5C can not only restore CD8+ T cell function and suppress tumor growth, but can also enhance the efficacy of anti‐PD1 therapy in NSCLC. The gene discussed is CD8A; the disease is neoplasm.